Abstract |
Seventeen patients with malignant mesothelioma were treated in a phase II study with carboplatin, a cisplatin analogue without significant nephrotoxicity or neurotoxicity. The drug was given in a dose of 300-400 mg/m2 by i.v. infusion, repeating at 28-day intervals. One patient achieved a complete clinical and radiological remission of 15 months' duration, and a second patient achieved a partial response of 11 months' duration (overall response rate 12%; overall response rate in previously untreated patients 20%). Four other previously untreated patients achieved symptomatic relief. Treatment was well tolerated without severe side-effects. Carboplatin, like most other cytotoxic drugs, is active only in a small minority of patients with mesothelioma, but its ability to achieve occasional good responses and frequent symptomatic relief, combined with low toxicity, may justify a short therapeutic trial in patients whose tumour is symptomatic.
|
Authors | E K Mbidde, S J Harland, A H Calvert, I E Smith |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 18
Issue 3
Pg. 284-5
( 1986)
ISSN: 0344-5704 [Print] Germany |
PMID | 3542270
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Organoplatinum Compounds
- Carboplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Carboplatin
- Drug Evaluation
- Female
- Humans
- Infusions, Intravenous
- Male
- Mesothelioma
(drug therapy)
- Middle Aged
- Organoplatinum Compounds
(administration & dosage, adverse effects, therapeutic use)
- Peritoneal Neoplasms
(drug therapy)
- Pleural Neoplasms
(drug therapy)
- Time Factors
|